137 related articles for article (PubMed ID: 36298622)
1. Post-Vaccination Neutralization Responses to Omicron Sub-Variants.
Jacobsen H; Katzmarzyk M; Higdon MM; Jiménez VC; Sitaras I; Bar-Zeev N; Knoll MD
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298622
[TBL] [Abstract][Full Text] [Related]
2. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.
Du Y; Chen L; Shi Y
Hum Vaccin Immunother; 2022 Nov; 18(5):2062983. PubMed ID: 35499517
[TBL] [Abstract][Full Text] [Related]
3. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
He X; Su J; Ma Y; Zhang W; Tang S
Front Immunol; 2022; 13():945930. PubMed ID: 36090988
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2.
Jacobsen H; Sitaras I; Katzmarzyk M; Cobos Jiménez V; Naughton R; Higdon MM; Deloria Knoll M
NPJ Vaccines; 2023 Oct; 8(1):159. PubMed ID: 37863890
[TBL] [Abstract][Full Text] [Related]
6. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination.
Suntronwong N; Assawakosri S; Kanokudom S; Yorsaeng R; Auphimai C; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892491
[TBL] [Abstract][Full Text] [Related]
7. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
8. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875
[TBL] [Abstract][Full Text] [Related]
9. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
10. Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants.
Springer DN; Bauer M; Medits I; Camp JV; Aberle SW; Burtscher C; Höltl E; Weseslindtner L; Stiasny K; Aberle JH
NPJ Vaccines; 2023 Aug; 8(1):110. PubMed ID: 37542025
[TBL] [Abstract][Full Text] [Related]
11. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1.
Davis-Gardner ME; Lai L; Wali B; Samaha H; Solis D; Lee M; Porter-Morrison A; Hentenaar IT; Yamamoto F; Godbole S; Douek DC; Lee FE; Rouphael N; Moreno A; Pinsky BA; Suthar MS
bioRxiv; 2022 Nov; ():. PubMed ID: 36380757
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal protection against Omicron.
Hao L; Hsiang TY; Dalmat RR; Ireton R; Morton J; Stokes C; Netland J; Hale M; Thouvenel C; Wald A; Franko NM; Huden K; Chu H; Greninger A; Tilles S; Barrett LK; Van Voorhis WC; Munt J; Scobey T; Baric RS; Rawlings D; Pepper M; Drain PK; Gale M
medRxiv; 2022 Aug; ():. PubMed ID: 36032965
[TBL] [Abstract][Full Text] [Related]
13. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.
Andeweg SP; de Gier B; Eggink D; van den Ende C; van Maarseveen N; Ali L; Vlaemynck B; Schepers R; Hahné SJM; Reusken CBEM; de Melker HE; van den Hof S; Knol MJ
Nat Commun; 2022 Aug; 13(1):4738. PubMed ID: 35961956
[TBL] [Abstract][Full Text] [Related]
14. The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination.
Hastert FD; Hein S; von Rhein C; Benz NI; Husria Y; Oberle D; Maier TJ; Hildt E; Schnierle BS
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632550
[TBL] [Abstract][Full Text] [Related]
15. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
[TBL] [Abstract][Full Text] [Related]
16. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant.
Richardson SI; Kgagudi P; Manamela NP; Kaldine H; Venter EM; Pillay T; Lambson BE; van der Mescht MA; Hermanus T; Balla SR; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; du Pisanie M; Burgers WA; Ntusi NAB; Abdullah F; Ueckermann V; Rossouw TM; Boswell MT; Moore PL
Cell Rep Med; 2023 Jan; 4(1):100910. PubMed ID: 36603577
[TBL] [Abstract][Full Text] [Related]
19. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs.
Bekliz M; Adea K; Vetter P; Eberhardt CS; Hosszu-Fellous K; Vu DL; Puhach O; Essaidi-Laziosi M; Waldvogel-Abramowski S; Stephan C; L'Huillier AG; Siegrist CA; Didierlaurent AM; Kaiser L; Meyer B; Eckerle I
Nat Commun; 2022 Jul; 13(1):3840. PubMed ID: 35787633
[TBL] [Abstract][Full Text] [Related]
20. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
